Have any questions? 706-721-6582 or cts@augusta.edu
The purpose of this study is to evaluate th effectiveness, safety, and tolerability of adding the investigational drug, Nivolumab, to concurrent chemoradiotherapy followed by treatment with Nivolumab and Ipilimumab or Nivolumab alone, in participants with stage 3, locally advanced non-small cell lung cancer. Participants in the control group will receive concurrent chemoradiotherapy followed by treatment with Durvalumab.